Topic

Found 728,010 articles

• Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

  5/8/2023

  23andMe Holding Co., a leading human genetics and biopharmaceutical company, announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups.

• Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related Diseases

  5/8/2023

  Life Biosciences and Forge Biologics today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications.

• The Special Committee of the Board of Directors of Liminal Biosciences Retains an Independent Financial Advisor in Response to Unsolicited Non-Binding Transaction Proposal

  5/8/2023

  Liminal BioSciences Inc., re-confirms that the board of directors of the Company has already established a special committee of the independent members of the Company's board of directors in respect to the previously announced unsolicited non-binding proposal from Structured Alpha LP to acquire all of the issued and outstanding common shares of the Company that SALP does not currently own for US$7.50 in cash per common share.

• Athira Pharma to Participate in Upcoming May 2023 Investor Conferences

  5/8/2023

  Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, announced that it will participate in the following upcoming investor conferences.

• Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting

  5/8/2023

  Natera, Inc. today announced the publication of a new paper 1 in Cancer Cell from the I-SPY2 trial, highlighting the prognostic and predictive utility of Natera’s personalized and tumor-informed, molecular residual disease (MRD) test, Signatera, in locally advanced breast cancer patients receiving neoadjuvant chemotherapy (NAC, treatment before surgery).

• AceLink Therapeutics Appoints Pedro Huertas, M.D., Ph.D., as Chief Medical Officer

  5/8/2023

  AceLink Therapeutics, Inc. today announced the appointment of Pedro Huertas, M.D., Ph.D., as Chief Medical Officer (CMO).

• Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

  5/8/2023

  Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2023, and provided an update on recent clinical and development pipeline progress.

• Conformis Reports First Quarter 2023 Financial Results

  5/8/2023

  Conformis, Inc., an orthopedic medical device company that features personalized knee and hip replacement products, announced financial results for the first quarter ended March 31, 2023.

• Scholar Rock to Present New Data Evaluating Apitegromab at 36 Months from the Phase 2 TOPAZ trial at the 2023 Annual Cure SMA Conference

  5/8/2023

  Scholar Rock announced today it will present extension data from the Phase 2 TOPAZ trial evaluating patient outcomes after 36 months of treatment with apitegromab.

• BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights

  5/8/2023

  BioXcel Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2023, and provided an update on key strategic initiatives.

• Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]

  5/8/2023

  Viatris Inc. (NASDAQ: VTRS) today reported strong results for the first quarter of 2023 reflecting another robust operational performance and instilling further confidence in the Company's ability to return to growth as it prepares to enter Phase 2 of its strategic plan in 2024.

• Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

  5/8/2023

  Marker Therapeutics, Inc. today announced the appointment of Monic Stuart, M.D., as its new Chief Medical Officer.

• Zevra Announces Board of Directors and Leadership Changes

  5/8/2023

  Zevra Therapeutics, Inc. today announced changes to the Company’s Board of Directors (“Board”) and leadership. At the Company’s recent 2023 Annual Meeting of Stockholders (“Annual Meeting”), Zevra shareholders elected John B. Bode, Douglas W. Calder and Corey Watton to Zevra’s Board.

• FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

  5/8/2023

  FibroGen, Inc. (Nasdaq: FGEN) and Fortis Therapeutics announced that FibroGen has entered into an exclusive license with Fortis Therapeutics for FOR46, a potential first-in-class Phase 1 antibody-drug conjugate (ADC) targeting a novel epitope on CD46.

• Pulmonary Fibrosis Foundation Urges Patients to Use Only FDA-Approved Oxygen Delivery Devices

  5/8/2023

  The medical advisory board of the Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education, and advocacy organization, has issued a position statement on non-prescription supplemental oxygen.

• Nephros Announces CEO Retirement and Succession Plan

  5/8/2023

  Nephros, Inc. today announced that Andy Astor, President and Chief Executive Officer, will retire in the coming months, and that Robert Banks will be named President and Chief Executive Officer effective on the first business day after the filing of Nephros’ Form 10-Q for the quarter ended March 31, 2023.

• ConcertAI's TeraRecon Expands AI Model and Clinical Collaboration Capabilities of Eureka Clinical AI

  5/8/2023

  ConcertAI's TeraRecon, the advanced visualization and clinical AI SaaS category leader, announced the launch of its enhanced, next-generation Eureka Clinical AI platform.

• Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China

  5/8/2023

  Chance Pharmaceuticals and Acorda Therapeutics, Inc. today announced that they have entered into distribution and supply agreements to provide INBRIJA ® in Greater China (Mainland China , Taiwan , Hong Kong , and Macao ). INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.

• Trefoil Therapeutics’ Lead Investigational Candidate TTHX1114 Improves Rate of Visual Recovery after Descemet Stripping Only (DSO) in Phase 2 STORM Data Presented at ASCRS Annual Meeting

  5/8/2023

  Trefoil Therapeutics today announced that TTHX1114 was found to improve the rate of visual recovery and corneal deturgescence (state of relative dehydration maintained by the normal cornea that is necessary for transparency) after Descemet Stripping Only (DSO) in a dose-responsive manner in the Phase 2 STORM study.

• Singlera Genomics Receives FDA Breakthrough Device Designation for PDACatch, a Liquid Biopsy Assay for Pancreatic Cancer Detection in High-Risk Individuals

  5/8/2023

  Singlera Genomics today announced that it had received Breakthrough Device Designation from the Food and Drug Administration (FDA) for its PDACatch assay, a novel DNA methylation-based liquid biopsy assay for the detection of pancreatic adenocarcinoma in individuals at high risk for the disease.